The maker of Olay just paid nearly $4 billion for a vitamins company, and the price tag is the message. On 4 August 2026, Procter & Gamble announced it will acquire supplements brand Thorne for $3.8 billion in cash, with CEO Shailesh Jejurikar confirming the deal in a CNBC interview, per Reuters. The transaction, expected to close in the fourth quarter of the fiscal year, marks P&G's largest recent bet on the premium wellness territory that beauty customers increasingly shop as an extension of their skincare routines.
All deal figures here come from the 4 August 2026 announcements and Reuters' reporting; they describe a corporate transaction, and nothing in it constitutes evidence for any supplement's effects.
What exactly did P&G buy?
A science-positioned, practitioner-trusted supplements brand. Thorne built its reputation on clinically validated formulations and testing transparency, selling direct to consumers and through health practitioners, per the brand's own positioning cited in deal coverage. P&G, whose beauty and grooming portfolio spans Olay, SK-II, and Pantene, gains an entry into ingestible wellness, the category its beauty customers already cross-shop.
Why is the price notable?
Because of what it says about the seller's three years. L Catterton, the private equity firm backed by LVMH, took Thorne private in 2023 in a deal valued at approximately $680 million, per Reuters' reporting. The $3.8 billion sale price represents roughly a six-fold increase in value in about three years, and coverage of the sale cited a reported internal rate of return near 77% for L Catterton's fund. Few consumer assets of this size have appreciated that quickly.
Does this change what beauty shoppers should expect?
Expect more aisle-blurring, not overnight product changes. The deal closes in the fourth quarter of the fiscal year, and integration follows; per the 4 August announcements, no product or distribution changes were announced. The strategic direction is the readable part: mass retailers and mass manufacturers are paying premium prices for credibility in science-backed wellness, because that is where label-reading customers are spending. P&G's own beauty brands have edged toward ingestible and skin-health claims for years, and owning Thorne gives that effort a brand with existing practitioner trust rather than a new build.
For readers who check concentrations and third-party testing seals, the acquisition is worth watching with the same scrutiny applied to any serum launch: the brand's testing and formulation standards are the asset P&G just paid for, and whether those standards survive corporate integration is the question the next two years will answer, per the terms announced on 4 August 2026.
For more context, read Coty Hands Gucci Beauty Back a Year Early, and L'Oréal Steps In.
For more context, read estee lauder puig talks end.
For more context, read estee lauder puig merger.